Watch the recording
Learn more about QuantSeq 3’ mRNA-Seq Library Prep Kit here.
Place an order here.
If you have any questions, do not hesitate contacting us at info@lexogen.com.
Abstract
This webinar discusses a study that compared nine different transcriptomic analysis technologies with matched fresh frozen (FF) and formalin-fixed paraffin-embedded (FFPE) cancer tissues.
Cost and tissue availability normally preclude processing samples across multiple technologies, making it difficult to directly evaluate performance, reliability, and to what extent gene expression data from different platforms can be compared or integrated. In order to explore the feasibility of integrating gene expression data from different platforms, Dr. Arran K. Turnbull of the Cancer Research UK Edinburgh Center and colleagues explored nine technologies, which varied in resolution, cost, and RNA requirements.
The study used sequential tumor biopsies from 11 postmenopausal women with estrogen receptor positive breast cancer treated with three months of neoadjuvant anti-estrogen therapy. Half of each sample was snap frozen in liquid nitrogen and half was FFPE.
Transcriptomic analyses were performed using the Illumina Beadarray, Affymetrix U133A, Affymetrix Clariom S, NanoString nCounter, AmpliSeq Transcriptome, Lexogen QuantSeq and IonXpress RNAseq, Tempo-Seq BioSpyder, and Qiagen UPX 3’.
Dr. Turnbull details the study’s findings, which include:
- Robust gene expression profiles can be reliably generated from FFPE tissues and are comparable to those derived from FF tissue using established transcriptomic approaches.
- A range of new technologies are available for the study of FFPE tissues; these vary in cost, resolution, and RNA requirements to fit the user’s needs.
- Gene expression data from biologically similar studies, generated using different technologies, can be reliably integrated for robust meta-analysis, subject to appropriate batch correction analysis.
Speaker’s biography
Dr. Arran K. Turnbull is a postdoctoral research fellow leading the lab-based research as part of the Edinburgh Breast Cancer Now Research Team and as group leader of the Translational Oncology Research Team at the MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh. His research work focuses on understanding, predicting, and treating resistance to endocrine therapy in breast cancer patients.
Dr. Turnbull has an undergraduate degree in molecular biology from Heriot-Watt University and an MRes in immunology, genetics, and pathway medicine from the University of Edinburgh. He graduated with a PhD in oncology and clinical medicine at the University of Edinburgh in 2012 and started his own research group in 2018.
